-+ 0.00%
-+ 0.00%
-+ 0.00%

J&J says Phase 3 FUZION trial shows TREMFYA delivers up to 28% perianal fistula remission in Crohn’s disease

PUBT·10/12/2026 20:06:02
Listen to the news
J&J says Phase 3 FUZION trial shows TREMFYA delivers up to 28% perianal fistula remission in Crohn’s disease
  • Johnson & Johnson disclosed new Phase 3 subgroup data for TREMFYA in Crohn’s disease patients with perianal fistulas.
  • Results were being presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.
  • TREMFYA delivered consistent fistula remission outcomes across difficult-to-treat groups, including patients previously treated with biologics.
  • Safety findings matched the drug’s established profile in Crohn’s disease, supporting its positioning in a high unmet-need complication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610121605PR_NEWS_USPR_____NY69911) on October 12, 2026, and is solely responsible for the information contained therein.